SABR-CaRe: A Phase II Randomized Trial of Pre-Operative Stereotactic Ablative Radiation Therapy (SABR) With and Without Caloric Restriction for Early Stage Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Percent reduction in cellularity of breast tumor
研究概览
简要总结
This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer. Stereotactic ablative radiation therapy (sABR) is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organ. Giving SABR before surgery may make the tumor smaller. Adding dietary restrictions in combination with radiation therapy may help increase local control and decrease the spread of the cancer to other places in the body. The purpose of this trial is to identify if there is a decrease in tumor tissue in patients undergoing caloric restriction during pre-operative SABR, compared to patients undergoing pre-operative SABR alone.
详细描述
PRIMARY OBJECTIVE:
I. To detect a decrease in cellularity of the tumor in participants undergoing caloric restriction during pre-operative SABR as compared to participants undergoing SABR alone.
SECONDARY OBJECTIVES:
I. Change in miR-21 as defined by baseline and post radiation levels. II. Investigate measurable changes of patient and tumor characteristics from the combination of SABR and caloric restriction (CR) versus SABR alone to inform future trials.
III. To describe pathologic complete response (pCR) rates as defined by no residual carcinoma or no residual invasive carcinoma, but ductal carcinoma in situ (DCIS) may be present, in each arm as well as by subtype.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Patients with pathologically proven DCIS or invasive breast cancer histologies
- •Willing and able to provide informed consent
- •Willing and able to comply with study treatments including dietary intervention
- •Body mass index (BMI) >= 21 at time of enrollment
- •Age >= 40 years at time of consent
- •* Patients with triple negative breast cancer (TNBC) must be >= 50 years of age at time of consent
- •Karnofsky performance status (KPS) score 70 - 100
- •Tumor size =< 3.0 cm
- •Gross disease within the breast must be unifocal
- •* Gross disease may be multifocal as long as the total extent of tumor, gross and microscopic, occupies a volume with greatest dimension =< 3 cm
- •Patients with invasive disease are required to have clinical axillary staging including axillary ultrasound (US) that proves patient is clinically node negative or can be done by physical examination if the patient is over 70
- •Patient is not being considered for preoperative chemotherapy
- •Must be English or Spanish speaking
排除标准
- •Patient is clinically node positive: clinically suspicious axillary lymph node(s) by axillary US or exam unless biopsied and found to be negative
- •Patient has stage IV metastatic disease
- •* Patients with oligo-metastatic disease who are being treated with curative intent per the treating physician will not be excluded if all other eligibility criteria are met
- •Breast tumor size is > 3.0 cm
- •Positive non-axillary sentinel nodes or evidence of suspicious supraclavicular, infraclavicular, or internal mammary nodes by imaging or physical exam, unless biopsied and found to be negative for tumor
- •Evidence by physical examination or mammography of other suspicious masses, densities, or microcalcifications in either breast, unless biopsied and found to be benign
- •Paget's disease of the nipple
- •Previous breast radiation on ipsilateral side
- •Any prior treatment with radiation therapy or chemotherapy for the current breast cancer diagnosis prior to registration
- •Patients with significant psychiatric illness that would preclude them from adhering to the protocol in the judgement of the treating clinician
- •BMI < 21 at the time of study enrollment
研究组 & 干预措施
Arm I (standard dietary recommendations, SABR, surgery)
Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Best Practice (Other)
Arm I (standard dietary recommendations, SABR, surgery)
Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Stereotactic Body Radiation Therapy (Radiation)
Arm I (standard dietary recommendations, SABR, surgery)
Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Resection (Procedure)
Arm I (standard dietary recommendations, SABR, surgery)
Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Sentinel Lymph Node Biopsy (Procedure)
Arm I (standard dietary recommendations, SABR, surgery)
Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Questionnaire Administration (Other)
Arm I (standard dietary recommendations, SABR, surgery)
Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Quality-of-Life Assessment (Other)
Arm I (standard dietary recommendations, SABR, surgery)
Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Mammography (Procedure)
Arm I (standard dietary recommendations, SABR, surgery)
Patients receive standard dietary recommendations. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Biospecimen Collection (Procedure)
Arm II (caloric restriction diet, SABR, surgery)
Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Stereotactic Body Radiation Therapy (Radiation)
Arm II (caloric restriction diet, SABR, surgery)
Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Resection (Procedure)
Arm II (caloric restriction diet, SABR, surgery)
Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Sentinel Lymph Node Biopsy (Procedure)
Arm II (caloric restriction diet, SABR, surgery)
Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Dietary Intervention (Other)
Arm II (caloric restriction diet, SABR, surgery)
Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Questionnaire Administration (Other)
Arm II (caloric restriction diet, SABR, surgery)
Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Quality-of-Life Assessment (Other)
Arm II (caloric restriction diet, SABR, surgery)
Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Mammography (Procedure)
Arm II (caloric restriction diet, SABR, surgery)
Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
干预措施: Biospecimen Collection (Procedure)
结局指标
主要结局
Percent reduction in cellularity of breast tumor
时间窗: 4-16 weeks, depending on the date of surgery
The mean percent reduction will be compared between the study arms using a two-sample two-sided t-test with alpha 0.05.
次要结局
- Feasibility of identifying sentinel lymph node (SLN)(After pre-operative SABR)
- Global physiologic assessment(Up to 6 months after SABR)
- Change in patient-reported health-related quality of life(Baseline to 6 months after SABR)
- Physician cosmesis evaluation(Up to 6 months after SABR)
- Rate of positive margins and need for re-excision(Up to 6 months after SABR)
- Rate of post-operative complications(Up to 6 months after SABR)
- Change in tumor stiffness, angiogenesis, and tumor size(Baseline and before surgery)